渤健Biogen (BIIB) 2010年年度报告「NASDAQ」.pdf

1、+ar2010!HAT!E O)EST+!HAT PATIE.TS.EE/OST+0121!#!$&()&*39107.indd i39107.indd i4,5,11 9:21:23 PM4,5,11 9:21:23 PM!i#$enide()(#*+,r./0/!I#!LI#!TS!C$O&/)iotechnologyCO&)U!I6!/789an$herape8!csP&O?UC$!/AAO6BCD$E!A)&ICD&I$UBA6CO$%&()&*+(LISSA TUF(LD!#$%&()*+,-./,COMMERCIAL 2*pr#4ed 56789:unit trends 9nr#e

2、d,!#ut 0?A/p,tients in tBe CD 4irus,ss,E tri,s in supp#rt#f GHS5JK2 risL str,tifi(,ti#n Mied pr#p#sed,!e upd,te NitB MO5,nd 9P5 t#in(ude,ntiQCD 4irus,nti!#dE st,tus,s#ne p#tenti,risL f,(t#r f#r RPS 7!t,ined MO5,ppr#4,f#r use#f K2GT:58,s,*,inten,n(e tBer,pE f#r n#nQU#d$LinVs E*pB#*,7!t,ined MO5,ppr#4

3、,f#r use#f K2GT:58 W MD f#r DO./Qp#siti4e DSS Su!*itted sJS5 f#r K2GT:58 in 58D5Q,ss#(i,ted 4,s(uitisOPERATIONAL AN-STRATE/IC D,rified Ji#$en 2de(Vs str,te$i(f#(us Stre,*ined tBe(#*p,nEVs stru(ture X eYpe(ted t#resut in,!#ut Z/P in,nnu,#per,tin$eYpense s,4in$s Uired t,ented neN e,ders in KO,nd D#rp#

4、r,te Oe4e#p*ent!#$%&indd ii!#$%&indd ii+,-,#./#.!PM+,-,#./#.!PM!BSINESS DE)ELOPMENTI#$%&()+,-./%,+0$10-ALS5.$(0 607.(L08 G:-%;8%-)?:-0$.?%A0)%(1-0/N8-%/8?:.?.)-(6=CNS?.-;?(S?-;?:)&0$.A0-.?%0 7%?:G?&:.)R0&:PIPELINEI%?%.?)P:.(F?-%.$10-).&$%G8/.A%/8$?%,$(&$-0(%(I%?%.?)-;%(?-.?%0.$?-%.$(10-$0;#$.(?%;-&0

5、/A%.?F.&?0-IIII F&%:/0,:%$%.A.)F.&?0-IX F&%:/0,:%$%.KI%?%.?)P:.(L LINGO-/=$%.?%0?-%.$I%?%.?)P:.(N KG#LN&0/A%.?%0?-%.$!ote:EPS numbers are diluted non-GAAP,which excludes the impact of purchase accounting,merger-related adjustments,stock option expense,other items and their related tax effects.Free c

6、ash!ow is de ned as net cash!ows provided by operating activities less purchases of property,plant and equipment,as disclosed within our Form 10-H.Ieconciliations of GAAP to non-GAAP diluted EPS and free cash!ow amounts are on pages 12-13 of this annual report.FREE CASH FLOW!in millions*!#!$!%!&!$64